Advancing TCRs for cellular therapy
In our push to use the wisdom of the adaptive immune system to potentially generate a new class of personalized therapeutics, we created our TruTCR process as part of our platform to enable the discovery of TCRs against clinically relevant antigens. In collaboration with Genentech, we plan to apply a similar process to screen and aim to identify in real-time what we believe are the most promising patient-specific TCRs targeting the patient’s specific cancer antigens, to advance the next generation of cellular therapy in oncology.
We are currently working to leverage our TCR discovery capabilities to enable commercialization of novel therapies by collaborators. In the future, we may explore expanding our end-to-end capabilities for the development of cellular therapies and vaccines.
TCR Characterization with TruTCR
To date, we have identified and characterized to different stages more than 1,200 unique antigen-specific TCRs against 600 different clinically relevant targets, constituting our pipeline of possible clinical candidates. TCR characterization using TruTCR is summarized in the figure below.
Several hundreds of antigens are used in conjunction with cells from healthy donor peripheral blood. This allows access to the massive diversity of a healthy repertoire to identify superior, potent TCRs against naturally processed and presented antigens.
2. TCR IDENTIFICATION
Candidate TCRs are first identified using immunoSEQ and our patented MIRA* (Multiplexed Identification of T-cell Receptor Antigen Specificity) assay to select T-cell receptors that effectively bind to any type of antigens that are processed and presented. We then use our proprietary pairSEQ* assay to create a complete sequence of both chains of these clinical candidates.
3. TCR CHARACTERIZATION
These TCRs are then synthesized and further characterized using a robust suite of cellular immunology assays including the assessment of TCR binding, cell killing, and set of de-risking safety steps to rule out any off-target effects. Prioritized TCRs are then developed by our partners into TCR-based cellular therapies ready for use in IND enabling studies.
immunoSEQ, MIRA, pairSEQ, and TruTCR are for Research Use Only. Not for use in diagnostic procedures.